Zacks Research Downgrades Gyre Therapeutics (NASDAQ:GYRE) to Strong Sell

Key Points

• Zacks Research downgraded Gyre Therapeutics from a "hold" to a strong sell, while analyst coverage is mixed overall with a MarketBeat consensus of "Hold" and a consensus price target of $17.00.
• GYRE shares opened at $7.01 (50-day/200-day averages ~ $7.96/$7.77) with a market cap of $679.7M and an extremely high trailing PE of 701.7, and the company missed EPS expectations in the latest quarter ($0.04 vs. $0.08) despite a slight revenue beat.
• Gyre is a clinical-stage biotech developing lipid-targeted small-molecule therapies across programs including NASH, Alzheimer’s and autoimmune conditions, with a primarily preclinical pipeline.

Gyre Therapeutics (NASDAQ:GYRE - Get Free Report) was downgraded by equities research analysts at Zacks Research from a "hold" rating to a "strong sell" rating in a research note issued to investors on Monday,Zacks.com reports.

Several other analysts have also recently commented on GYRE. Wall Street Zen cut shares of Gyre Therapeutics from a "buy" rating to a "hold" rating in a research note on Saturday, March 14th. Weiss Ratings restated a "sell (d)" rating on shares of Gyre Therapeutics in a research report on Thursday, January 22nd. Two research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company's stock. According to data from MarketBeat.com, Gyre Therapeutics presently has a consensus rating of "Hold" and a consensus price target of $17.00.

Gyre Therapeutics Price Performance

Shares of GYRE stock opened at $7.01 on Monday. The business's fifty day moving average price is $7.96 and its 200 day moving average price is $7.77. The firm has a market capitalization of $679.69 million, a PE ratio of 701.70 and a beta of 1.97. Gyre Therapeutics has a 1-year low of $6.11 and a 1-year high of $11.78.

Gyre Therapeutics (NASDAQ:GYRE - Get Free Report) last released its earnings results on Thursday, March 12th. The company reported $0.04 EPS for the quarter, missing analysts' consensus estimates of $0.08 by ($0.04). The business had revenue of $37.20 million during the quarter, compared to analyst estimates of $36.30 million. Gyre Therapeutics had a net margin of 4.31% and a return on equity of 10.85%.

Institutional Trading of Gyre Therapeutics

Several large investors have recently bought and sold shares of the company. State of Alaska Department of Revenue acquired a new position in shares of Gyre Therapeutics during the 3rd quarter worth $38,000. Bank of America Corp DE grew its stake in Gyre Therapeutics by 28.8% in the 2nd quarter. Bank of America Corp DE now owns 6,277 shares of the company's stock valued at $46,000 after acquiring an additional 1,402 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in Gyre Therapeutics by 84.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 6,461 shares of the company's stock valued at $47,000 after acquiring an additional 2,961 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Gyre Therapeutics by 77.8% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,413 shares of the company's stock valued at $54,000 after acquiring an additional 3,244 shares in the last quarter. Finally, Dimensional Fund Advisors LP acquired a new position in Gyre Therapeutics during the fourth quarter worth about $77,000. Institutional investors and hedge funds own 23.99% of the company's stock.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company's proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.

Gyre's preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer's disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.